Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer

Journal of Managed Care Pharmacy

Volumn 19, Issue 9, 2013, Pages 799-808

  Sorensen, Sonja ^a   Ellis, Lorie ^b   Wu, Ying ^c   Hutchins, Valerie ^d   Linnehan, John E ^d   Senbetta, Mekré ^c  

^a EVIDERA   (United States)

^b Health Economics and Outcomes Research   (United States)

^c Oncology Nephrology Outcomes Research   (United States)

^d UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PREDNISONE;

ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG COST; FATIGUE; FEBRILE NEUTROPENIA; HEALTH CARE PLANNING; HUMAN; HYPOKALEMIA; MEDICARE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRACTICE GUIDELINE; PREVALENCE; REIMBURSEMENT; RETREATMENT; SENSITIVITY ANALYSIS; THROMBOCYTOPENIA; TREATMENT DURATION;

ANDROSTENOLS; BUDGETS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MODELS, ECONOMIC; ORCHIECTOMY; PREDNISONE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 84888401401     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.9.799     Document Type: Article

References (42)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc- 026238.pdf. Accessed July 8, 2013.
2. National Cancer Institute. Cancer trends progress report 2009/2010 update. 2010. Available at: http://www.cancer.gov/newscenter/newsfromnci/2010/ProgressReport2010. Accessed August 19, 2013.
3. Solo K, Mehra R, Dhawan R, et al. Prevalence of prostate cancer (PC) clinical states (CS) in the United States: Estimates using a dynamic progression model. J Clin Oncol. 2011;29(Suppl):abs-4637.
4. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res. 2005;11(14):5223-32.
5. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-24.
6. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036-42.
7. Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology. 2001;57(4):727-32.
8. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12.
9. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
10. Jevtana (cabazitaxel) injection, 60 mg/1.5 mL, intravenous infusion (IV) [package insert]. Sanofi-aventis. Revised May 2013. Available at: http://products. sanofi.us/jevtana/jevtana.html. Accessed August 19, 2013
11. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
12. Zytiga (abiraterone acetate) tablets. Janssen Biotech. December 2012. Available at: http://www.zytiga.com/sites/default/files/pdf/full_product_ information.pdf. Accessed September 23, 2013.
13. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-92.
14. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007;10(5):336-47.
15. FMCP Format Executive Committee. The AMCP format for formulary submissions, version 3.0. A format for submission of clinical and economic evidence of pharmaceuticals in support of formulary consideration. Foundation for Managed Care Pharmacy and Academy of Managed Care Pharmacy. October 2009. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9127. Accessed July 8, 2013.
16. Johnson & Johnson. Ingenix Employer database from 2002 to 2008-Data on file. 2011.
17. U.S. Census Bureau. Annual estimates of the residential population by sex and five-year age groups for the United States, July 1, 2009. Available at: http://www.census.gov/popest/data/historical/2000s/vintage_2009/index. html. Accessed August 5, 2010.
18. U.S. Census Bureau. U.S. Interim projections by age, sex, race, and Hispanic origin: 2000-2050. Available at: http://www.census.gov/population/projections/data/national/usinterimproj.html. Accessed July 13, 2013.
19. Choueiri TK, Xie W, D'Amico AV, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009;115(5):981-87.
20. Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res. 2008;14(14):4526-31.
21. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113(9):2478-87.
22. Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008;112(6):1247-53.
23. Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ. 2012;15(5):836-43.
24. Janssen Biotech Inc. Data on file. Janssen Biotech, Inc.
25. Academy of Managed Care Pharmacy. AMCP guide to pharmaceutical payment methods, 2009 update (version 2.0). J Manag Care Pharm. 2009;15(6 Suppl A):S1-S61. Available at: http://www.amcp.org/data/jmcp/1002.pdf.
26. Novantrone (mitoXANTRONE) injection concentrate, intravenous infusion (IV) [package insert]. EMD Serono. May 2010. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2010/019297s033s034lbl.pdf. Accessed August 19, 2013.
27. Taxotere (docetaxel) injection concentrate, intravenous infusion (IV) [package insert]. Sanofi-aventis. Revised May 2010. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2010/020449s059lbl.pdf. Accessed July 8, 2013.
28. Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced nonsmall cell lung cancer. J Manag Care Pharm. 2009;15(8):669-82. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8233.
29. Agency for Healthcare Research and Quality. Healthcare cost and utilization project (HCUP). Nationwide inpatient sample (NIS). 2009. Available at: http://www.ahrq.gov/data/hcup/. Accessed July 8, 2013.
30. U.S. Department of Labor. Bureau of Labor Statistics. Archived Consumer Price Index detailed report information. 2007 Consumer Price Index detailed report. Available at: http://www.bls.gov/cpi/cpi_dr.htm#2000. Accessed July 8, 2013.
31. Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy- induced anemia. Support Care Cancer. 2012;20(1):159-65.
32. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: cancer- and chemotherapy-induced anemia. 2011. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines. asp"/l "anemia. Accessed July 8, 2013.
33. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: cancer-related fatigue. 2011. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp"/l "fatigue. Accessed July 8, 2013.
34. Centers for Medicare and Medicaid Services. Physician fee schedule. National payment amount file CY 2012. February 29, 2012. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-National-Payment-Amount-File.html. Accessed July 8, 2013.
35. RED BOO K Online. 2011 ed. Montvale, NJ: Thomson Healthcare; 2011: Available at: http://www.micromedexsolutions.com/home/dispatch. Accessed August 19, 2013.
36. MAG Mutual Healthcare Solutions Inc. Physicians' Fee & Coding Guide, 2012. Vol 1. Duluth, GA: Mag Mutual Healthcare Solutions Inc.; 2012.
37. Centers for Medicaid and Medicare Services. Medicare Part B drug average sales price. January 2012 ASP pricing file and not otherwise classified pricing file. 2011. Available at: http://www.cms.gov/Medicare/Medicare-Feefor- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2012ASPFiles.html. Accessed September 23, 2013.
38. Ho J, Zhang L, Todorova L, Whillans F, Corey-Lisle P, Yuan Y. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer. J Manag Care Pharm. 2009;15(6):467-75. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8179.
39. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm. 2006;12(6):472-78. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=7414.
40. Xtandi (enzalutamide capsules). Medivation, Inc. and Astellas Pharma US. 2012. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm317997.htm. Accessed July 8, 2013.
41. RED BOO K Online. 2012 ed. Montvale, NJ: Thomson Healthcare; 2012: Available at: http://www.micromedexsolutions.com/home/dispatch. Accessed August 19, 2013.
42. Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X. The economic burden of prostate cancer, California, 1998. Cancer. 2002;94(11):2906-13.